does clinicaltrials.gov list about 306 clinical trials on psilocybin?
“There's 306 clinical trials on psilocybin at clinicaltrials.gov as of this morning.”
a guest, a mycologist said on Huberman Lab, 2026-11-16, at 1:32:45. hear it in context → the speaker cited: clinicaltrials.gov.
first, the part that holds
the number holds up. when we queried the ClinicalTrials.gov registry the day after the episode aired, it returned 310 studies listing psilocybin as an intervention, 300 of them interventional trials. "about 306" matches what the registry shows.
what we found when we went and looked
on 2026-11-17 we queried the ClinicalTrials.gov public API for studies with psilocybin in the intervention field. it returned 310 records. a search for psilocybin in any field returned 328, and restricting to interventional study type gave 300. a count of 306 the previous morning sits inside that range. a peer-reviewed registry analysis that searched the same database on 12/12/2023 found 147 hits and 134 trials that listed psilocybin as an intervention, so registrations have more than doubled in under three years. the count measures registrations, not results: 93 of the 310 records are marked completed, and the 2023 analysis found results posted for 9 of its 28 completed trials.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| ClinicalTrials.gov lists about 306 studies on psilocybin | confirmed | our API query on 2026-11-17 returned totalCount 310 for psilocybin in the intervention field, and 328 for psilocybin in any field. the difference from 306 fits one day of new registrations plus a different search box. we could not see the exact query the speaker ran. [1] |
| these listings are clinical trials | confirmed | filtering the intervention-field search to study type 'interventional' left 300 of the 310 records. the remaining ~10 are observational or other study types. the registry counts every status, so the 310 also includes trials that are withdrawn, terminated, not yet recruiting or still running. [1] |
| psilocybin registrations have grown fast | confirmed | a peer-reviewed analysis searched ClinicalTrials.gov on 12/12/2023, found 147 hits for 'psilocybin' and kept 134 that listed it as an intervention. today's comparable figures are 328 and 310, a little more than double. the FDA's guidance on psychedelic clinical investigations, finalized in July 2026, says interest in psychedelics' therapeutic potential 'has been increasing'. [1][2] |
| popular framing: 300-plus trials means 300-plus sets of evidence | misattributed | a registration is a plan, not a result. 93 of the 310 records are marked completed. in the 2023 analysis, 28 of 134 trials (20.9%) were complete, results were posted for 9, 27 enrolled only healthy volunteers, and just 3 or 4 were phase 2/3 or phase 3 (the paper's own text disagrees with itself on that). the authors described 'little real progress towards FDA approval' and zero marketing approvals at that time. [1] |
both directions
for the speaker: the live registry count (310 by intervention field, 328 by any field, 300 interventional trials) brackets the speaker's 306 closely, and the speaker named the source and the timing. the registry analysis that searched in December 2023 shows the number was less than half as large then, so the speaker's broader point that psilocybin is now heavily studied is backed by the registry's own growth. the FDA's finalized 2026 guidance on psychedelic clinical investigations also describes interest as increasing.
against: nothing contradicts the number. the risk is in what listeners take from it. a registry entry is a plan filed by sponsors and investigators: the count includes withdrawn, terminated, not-yet-recruiting and observational records. fewer than a third (93 of 310) are marked completed. the most recent peer-reviewed breakdown we read found results posted for only 9 trials, many small or open-label studies, healthy-volunteer studies as the most common single "condition", and almost no late-phase trials. a count of trials shows how much research activity there is. it does not show whether psilocybin works for any particular condition.
what this cannot say
the registry count changes every day and depends on which search field is used. we got 310, 328 or 300 depending on the query, and we cannot reproduce the exact search the speaker ran the morning before. the episode may also have been recorded earlier than its 2026-11-16 air date. we read the count from the ClinicalTrials.gov public API (clinicaltrials.gov/api/v2/studies?query.intr=psilocybin&countTotal=true). that host is not on our citation list, so the registry query cannot appear as a linked source here, and anyone can rerun it. the peer-reviewed breakdown dates from December 2023 and its authors work for and hold stock in a psychedelic drug developer, which funded the paper. we did not check how many of today's completed trials have posted results, and we did not check the current approval status of any psilocybin product.
sources, each one fetched and read
- Norring SA, Spigarelli MG. The promise of therapeutic psilocybin: an evaluation of the 134 clinical trials, 54 potential indications, and 0 marketing approvals on ClinicalTrials.gov. Drug Design, Development and Therapy, 2024;18:1143-1151. doi:10.2147/DDDT.S443177 What we read there: ClinicalTrials.gov searched 12/12/2023 for 'psilocybin': 147 hits, 134 listing psilocybin as an intervention; 28 (20.9%) completed, results posted for 9; 27 trials list healthy participants as the condition; 54 indications; 0 marketing approvals; authors describe 'little real progress towards FDA approval'. authors are employees and shareholders of a psychedelic drug developer that funded the work. Fetched 2026-11-17 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC11016263/
- U.S. Food and Drug Administration. Psychedelic drugs: considerations for clinical investigations. Final guidance, July 2026 (finalizes the June 26, 2023 draft) What we read there: says interest in the therapeutic potential of psychedelic drugs 'has been increasing'. gives no trial count and does not state approval status. Fetched 2026-11-17 (HTTP 200). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam